The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
The study was conducted in patients with mild to moderate COVID-19
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
Their feedback and the consequent changes in software/protocols based on those inputs were deliberated upon.
Approval makes it the first and only therapy in the EU indicated for both acute and chronic hepatitis C, supported by Phase 3 data
As competition intensifies in the obesity treatment market, a next-generation therapy may be in development.
The findings come from the first and only decentralized real-world study examining how HD chorea affects patients and caregivers and how treatment impacts quality of life
The collaboration comes at a time when access to high-quality fertility treatment remains uneven, despite rapid market expansion
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
